<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04973787</url>
  </required_header>
  <id_info>
    <org_study_id>MicroSpA</org_study_id>
    <nct_id>NCT04973787</nct_id>
  </id_info>
  <brief_title>The Role of Microbiome on Biological Therapy Efficacy in axSpA and RA</brief_title>
  <acronym>MicroSpA &amp; RA</acronym>
  <official_title>MicroSpA &amp; MicroRA: The Role of Microbiome on Biological Therapy Efficacy in Axial Spondyloarthritis and Rheumatoid Arthritis - a New Paradigm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Nova de Lisboa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NOVA Medical School of Universidade NOVA de Lisboa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Hospitalar Lisboa Ocidental Hospital Egas Moniz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Hospitalar Universitário de São João</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Hospitalar de Vila Nova de Gaia/Espinho</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Hospitalar Universitário de Lisboa Norte - Hospital de Santa Maria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Português de Reumatologia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Hospitalar Médio Tejo - Hospital Rainha Santa Isabel - Torres Novas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Hospitalar Baixo Vouga - Hospital Infante D. Pedro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHRC-Comprehensive Health Research Centre, FCM|NMS, UNL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>iNOVA4Health - Rheumatic Diseases Lab</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unidade Local de Saúde do Alto Minho, Hospital Conde de Bertiandos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Braga E.P.E.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Sousa Martins - Unidade de Saúde Local da Guarda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Nova de Lisboa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spondyloarthritis (SpA) and Rheumatoid arthritis (RA) are among the most common chronic&#xD;
      inflammatory rheumatic diseases. Introduction of Tumor Necrosis Factor alpha inhibitors&#xD;
      (TNFi) to the therapeutic strategy improved acute inflammation and pain, but a significant&#xD;
      percentage of patients develop severe adverse events or are still non responders or&#xD;
      incomplete responders to these expensive treatments. There is an urgent need to identify new&#xD;
      predictors of biological therapy response. It has been described the role of microbiota in&#xD;
      some rheumatic diseases, however, clinical trials are scarce. We hypothesized that microbiota&#xD;
      or their metabolites may play a role in therapeutic response to TNFi.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thus, this project aimed to evaluate the influence of oral and gut microbiota in the&#xD;
      therapeutic response to biologic therapies, in 60 patients.&#xD;
&#xD;
      It is expected to enrolled 30 SpA and 30 RA patients and 30 controls, crossed by gender, age&#xD;
      and diet profile. Oral and fecal microbiota will be characterized before TNFi therapeutic.&#xD;
      Patients will have an additional microbiota and metabolic profile characterization 14 weeks&#xD;
      late after.&#xD;
&#xD;
      This will allow to identify specific profiles of oral and gut microbiome and/or specific&#xD;
      biochemical patterns in these patients. At week 14 it will be possible to identify changes&#xD;
      induced by TNFi. In addition, it will be possible to identify microbiota pattern associated&#xD;
      clinical therapeutic TNFi response vs non-response.&#xD;
&#xD;
      This will allow to predict isolate microbe or microbes patterns at baseline associated to&#xD;
      clinical response obtained at week 14. These results may additionally contribute to clinical&#xD;
      decision and a better evidenced-based treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>14 Weeks</target_duration>
  <primary_outcome>
    <measure>Oral and gut microbiota characterization in axSpA and RA patients at baseline</measure>
    <time_frame>Before bDMARD</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral and gut microbiota characterization in axSpA and RA patients at week 14</measure>
    <time_frame>14 weeks after start bDMARD</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease activity measured by ASAS20 in axSpA and ACR20 in RA</measure>
    <time_frame>14 weeks after start bDMARD</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Erythrocyte Sedimentation Rate (ESR, measured in mm/h)</measure>
    <time_frame>Before bDMARD and 14-week after start bDMARD</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in High-sensitivity C-reactive protein (hsCRP, measured in mg/dL)</measure>
    <time_frame>Before bDMARD and 14-week after start bDMARD</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity characterization using Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in axSpA</measure>
    <time_frame>Before bDMARD and 14-week after start bDMARD</time_frame>
    <description>Scale from 0 (worse outcome) to 10 (better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity characterization using Ankylosing Spondylitis Disease Activity Score - C-Reactive Protein (ASDAS-CRP) in axSpA</measure>
    <time_frame>Before bDMARD and 14-week after start bDMARD</time_frame>
    <description>&lt; 1.3 Inactive disease; &gt; 3.5 Very high disease activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity characterization using Disease Activity Score-28 for Rheumatoid Arthritis with C-Reactive Protein (DAS28-CRP) for RA</measure>
    <time_frame>Before bDMARD and 14-week after start bDMARD</time_frame>
    <description>Score greater than 5.1 implies active disease, less than 3.2 low disease activity, and less than 2.6 remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluation with Short form 36 (SF36) at baseline and week 14</measure>
    <time_frame>Before bDMARD and 14-week after start bDMARD</time_frame>
    <description>Score from 0 (worse outcome) to 100 (better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluation with Ankylosing Spondylitis Quality of Life (ASQOL) at baseline and week 14</measure>
    <time_frame>Before bDMARD and 14-week after start bDMARD</time_frame>
    <description>Range from 0 -18 - High scores indicate worse quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluation with Health Assessment Questionnaire (HAQ) at baseline and week 14</measure>
    <time_frame>Before bDMARD and 14-week after start bDMARD</time_frame>
    <description>Scores of 0 to 1 are generally considered to represent mild to moderate difficulty, 1 to 2 moderate to severe disability, and 2 to 3 severe to very severe disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluation regarding depression and anxiety using Hospital Anxiety and Depression Scale (HADS) at baseline and week 14</measure>
    <time_frame>Before bDMARD and 14-week after start bDMARD</time_frame>
    <description>Scores of less than 7 indicate non-cases; 8-10 Mild; 11-14 Moderate;15-21 Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue evaluation at baseline and week 14</measure>
    <time_frame>Before bDMARD and 14-week after start bDMARD</time_frame>
    <description>Visual analogic scale (0-10)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Axial Spondyloarthritis</condition>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>axSpA</arm_group_label>
    <description>Patients with clinical diagnosis of axialSpondyloarthritis according to ASAS criteria, with indication for bDMARD (Portuguese Rheumatology Society Guidelines)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RA</arm_group_label>
    <description>Patients with clinical diagnosis of Rheumatoid arthritis according to 2010 ACR/EULAR classification criteria, with indication for bDMARD (Portuguese Rheumatology Society Guidelines)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy participants, e.g. with no clinical diagnosis of rheumatic inflammatory disease, crossed by age, gender and diet profile</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>biological disease-modifying antirheumatic drugs (bDMARDs)</intervention_name>
    <description>bDMARD therapy (TNF inhibitors), according to the Portuguese recommendations for the use of biological therapies in patients with axSpA and RA</description>
    <arm_group_label>RA</arm_group_label>
    <arm_group_label>axSpA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with axSpA or RA according to ASAS and 2010 ACR/EULAR classification criteria,&#xD;
        respectively, with indication to start bDMARD according to Portuguese Rheumatology Society.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of axSpA (according to ASAS classification criteria) or RA (according to&#xD;
             2010 ACR/EULAR classification criteria);&#xD;
&#xD;
          2. Indication for bDMARD therapy, according to the Portuguese recommendations for the use&#xD;
             of biological therapies in patients with axSpA and RA;&#xD;
&#xD;
          3. Oral corticosteroids (equivalent to prednisolone ≤ 10mg/day) and/or nonsteroidal&#xD;
             anti-inflammatory drugs allowed at stable dose ≥4 weeks before baseline;&#xD;
&#xD;
          4. Conventional DMARDs allowed at stable dose ≥12 weeks before baseline;&#xD;
&#xD;
          5. Ability to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of rheumatic disorder other than axSpA or RA;&#xD;
&#xD;
          2. History of Inflammatory Bowel Disease;&#xD;
&#xD;
          3. Previous treatment with bDMARD;&#xD;
&#xD;
          4. Current pregnancy or breastfeeding;&#xD;
&#xD;
          5. Malignancy (except for completely treated squamous or basal cell carcinoma);&#xD;
&#xD;
          6. Any uncontrolled medical condition (e.g., uncontrolled diabetes mellitus, unstable&#xD;
             ischemic heart disease);&#xD;
&#xD;
          7. History of any documented gastrointestinal disease or tract surgery leaving permanent&#xD;
             residua (e.g., gastrectomy, bariatric surgery, or colectomy);&#xD;
&#xD;
          8. Intraarticular injections of extra-axial joints and tendons within 28 days before or&#xD;
             at baseline;&#xD;
&#xD;
          9. Recent (&lt;3 months prior) use of any antibiotic therapy, current extreme diet (e.g.,&#xD;
             parenteral nutrition or macrobiotic diet), current consumption of probiotics.&#xD;
&#xD;
        Control group will be healthy participants, and the same inclusion and exclusion criteria&#xD;
        will be applied except for rheumatic disease diagnosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Faria, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NOVA Medical School, Universidade Nova de Lisboa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Pimentel-Santos, PhD Agg</last_name>
    <role>Principal Investigator</role>
    <affiliation>NOVA Medical School, Universidade NOVA de Lisboa; CHLO Hospital Egas Moniz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Faria, PhD</last_name>
    <phone>00351218803033</phone>
    <email>ana.faria@nms.unl.pt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fernando Pimentel-Santos, PhD Agg</last_name>
    <phone>00351917305093</phone>
    <email>pimentel.santos@nms.unl.pt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro Hospitalar Baixo Vouga - Hospital Infante D. Pedro</name>
      <address>
        <city>Aveiro</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anabela Barcelos, MD</last_name>
      <email>barcelos.anabela@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Braga, E.P.E.</name>
      <address>
        <city>Braga</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Ribeiro, MD</last_name>
      <email>anaroxoribeiro@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sousa Martins - Unidade de Saúde Local da Guarda</name>
      <address>
        <city>Guarda</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cláudia Vaz, MD</last_name>
      <email>claudiacvaz@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Ocidental - Hospital Egas Moniz</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Pimentel-Santos, PhD Agg</last_name>
      <phone>00351917305093</phone>
      <email>pimentel.santos@nms.unl.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário de Lisboa Norte - Hospital Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elsa Vieira-Sousa, MD, PhD</last_name>
      <email>elsacvsousa@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Português de Reumatologia</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helena Santos, MD</last_name>
      <email>helena.santos@ipr.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário São João</name>
      <address>
        <city>Oporto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Miguel Bernardes, PhD</last_name>
      <email>mbernardes09@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidade Local de Saúde do Alto Minho, Hospital Conde de Bertiandos</name>
      <address>
        <city>Ponte de Lima</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Costa, MD</last_name>
      <email>josecosta99@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Médio Tejo - Hospital Rainha Santa Isabel - Torres Novas</name>
      <address>
        <city>Torres Novas</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>João Madruga-Dias, MD</last_name>
      <email>joao_alexandre@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Vila Nova da Gaia/Espinho</name>
      <address>
        <city>Vila Nova De Gaia</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrícia Pinto, MD</last_name>
      <email>patriciaampinto@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tumor Necrosis Factor alpha inhibitor</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

